Atezolizumab PK Fact Sheet

Details

Generic Name	Atezolizumab.
Trade Name	Tecentriq®.
Class	Antineoplastic agents, monoclonal antibody.
Molecular Weight	~145 kDa[1].

Summary of Key Pharmacokinetic Parameters

Linearity/non-linearity	Exposure increases in a dose-proportional manner over the dose range 1-20 mg/kg, and at the fixed dose 1,200 mg every 3 weeks.
Steady state	Achieved after 6-9 weeks of repeated dosing.
Plasma half-life	27 days.
Cmax	Not reported.
Cmin	Not reported.
AUC	Not reported.
Bioavailability	Administered IV.
Absorption	Administered IV.
Protein Binding	Not reported.
Volume of Distribution	6.91 L (PopPK).
Renal Clearance	Not reported.
Renal Impairment	No dose adjustment required for patients with mild to moderate renal impairment.
	The effect of severe renal impairment on atezolizumab pharmacokinetics is unknown.
Hepatic Impairment	No dose adjustment required for patients with mild to moderate hepatic impairment.
	The effect of severe hepatic impairment on atezolizumab pharmacokinetics is unknown.

Metabolism and Distribution

Metabolised by	Catabolised through non-specific pathways.
Inducer of	None reported.
Inhibitor of	None reported.
Transported by	None reported.

References

Unless otherwise stated (see below), information is from:

Tecentriq 1,875 mg solution for injection Summary of Product Characteristics, Roche, January 2024.

Tecentriq US Prescribing Information, Genentech Inc, April 2023.

1. Atezolizumab. Bethesda (MD): National Institute of Child Health and Human Development. Drugs and Lactation Database (LactMed®) [Internet], 2006-. [Updated 15/04/2023, accessed 27/02/24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500809/